Brazil Revises Stability Study Standards To Bring Companies More Certainty
Brazil’s medicines regulator ANVISA intends to update its criteria for stability studies for medicines so as to bring them into line with ICH guidelines and give drug developers more certainty.
You may also be interested in...
Brazil and South Korea have been accepted as new regulatory members of the International Council for Harmonisation. This has raised expectations that ICH guidelines will gain full acceptance in both countries, making it easier for the global innovative pharmaceutical industry to market their products there.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.